Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy and Reduced Radiotherapy for Intracranial Germinoma
NCT02782754Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jan 2013
- Primary completion
- Dec 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, etoposide, cyclophosphamide and bleomycin in intracranial germinoma, sponsored by Samsung Medical Center. Primary endpoint: Rate of late sequelae at 5 years. Status: unknown.
02
Drugs
carboplatinetoposidecyclophosphamidebleomycin
03
Conditions
intracranial germinoma
Beyond the preview
Go deeper on NCT02782754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782754.